Scott A. Laurie

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

Keunchil Park, Eng-Huat Tan, Kenneth J. O’Byrne et al. · The Lancet Oncology · 2016 · 1.1K citations

Oncology, Phase 2B, Pathology +8

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

Matthew D. Hellmann, Naiyer A. Rizvi, Jonathan W. Goldman et al. · The Lancet Oncology · 2016 · 945 citations · Full text

Multicohort Study, Checkmate 012, Medicine +7

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

Luis Paz‐Ares, E.H. Tan, Kenneth J. O’Byrne et al. · Annals of Oncology · 2017 · 512 citations · Full text

Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Scott Gettinger, Naiyer A. Rizvi, Laura Q.M. Chow et al. · Journal of Clinical Oncology · 2016 · 493 citations · Full text

Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Naiyer A. Rizvi, Matthew D. Hellmann, Julie R. Brahmer et al. · Journal of Clinical Oncology · 2016 · 442 citations · Full text